AZD2389

Pipeline

Status by Indication[3][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics3 trials

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06138795·120 enrolled

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06846528·16 enrolled

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Completed·AstraZeneca·Phase 1·NCT06974565·16 enrolled

Liver Fibrosis3 trials

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

Recruiting·AstraZeneca·Phase 2·NCT07610837·104 enrolled

A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).

Completed·AstraZeneca·Phase 1·NCT07069725·8 enrolled

A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis

Completed·AstraZeneca·Phase 2·NCT06750276·40 enrolled

Hepatic Impairment1 trial

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

Completed·AstraZeneca·Phase 1·NCT06812780·35 enrolled

Midazolam1 trial

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06973005·16 enrolled

Details

Drug Info

Related News